《全球商业报告（GBR）：2023年美国生命科学行业报告（英文版）（39页）.pdf》由会员分享，可在线阅读，更多相关《全球商业报告（GBR）：2023年美国生命科学行业报告（英文版）（39页）.pdf（39页珍藏版）》请在三个皮匠报告上搜索。

1、GBR SERIESUNITED STATESLIFE SCIENCES2023GBR SERIESFinance-Regulatory Climate-Clusters-AcademiaDrug Discovery and Development-Contract Services-New TechnologiesDear Reader,Welcome to the 2023 edition of the United States Life Sciences industry report.In many ways,2022 was a turning point for the US l

2、ife sciences industry.After having ex-perienced a record number of deals,IPOs,and drug approvals in 2020 and 2021,the past year was marked by post-pandemic recovery,macroeconomic shockwaves,and regulatory changes that industry leaders fear could cool the industrys expansion going forward.Yet,positiv

3、e signs point toward another year of growth for the life sciences industry.With large pharma firms on the hunt for new technologies to bolster their drug pipelines,deal-making and M&As have already seen an uptick in 2023.And as the giants go on the hunt for biotechs most promising discoveries,that i

4、nflux in capital estimated at over US$1 trillion will benefit investment throughout the whole industry.Companies are also adapting their long-term strategies to consider the future effects of the Inflation Reduction Act on the industry.The latter was received with mixed feelings by life sciences lea

5、ders,who,when it came to negotiating drug prices that will affect their margins,recalled the importance of ongoing R&D expenditure to prevent unsighted events,such as Covid-19.Biopharma and biotechs can rely on multiple allies on the road from discovery to com-mercialization:the CDMO,CMO,CRO,and ser

6、vices segments of the industry have never looked so healthy.This segment continued to strengthen in 2022,as the onshoring of manufacturing capabilities in the US,the push for green chemistry,and the need for skilled labor to industrialize promising technologies such as cell and gene therapies contin